ClinicalTrials.gg
CompletedNCT06548945Updated Aug 14, 2024

A Phase I Study of GZR18 Injection in Obese/Overweight Subjects

A Phase 1 interventional study of GZR18 and Placebo in Overweight and Obesity, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-08-14.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Apr 2023, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
14th of 15
16 · median 140
Started
2023
with 1 other
Phase 1
7 of 15
none open now
Registered
3rd of 15
by date
Lead sponsor
5 of 15
Gan and Lee Pharmaceuticals, USA

Among the 15 studies testing bofanglutide in Obesity, this one is the 14th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 3rd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study. A sequential design is used in this trial with a single dose escalation climb test, to investigate the safety, tolerability, and PK/PD characteristics of GZR18 injection in Chinese obese/overweight subjects.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 16 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Gan and Lee Pharmaceuticals, USA is the lead sponsor of 29 studies on the registry; 5 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects sign the form (ICF) voluntarily.
  • Chinese adult subjects, both male and female.
  • 18 to 65 years old (including both ends) at screening.
  • ≥26.0 kg/m2 at screening.
  • Stable weight before screening (i.e. self-reported weight change less than 5 kg within 8 weeks before screening).
  • Female subjects have negative serum Human Chorionic Gonadotropin (HCG) during screening and baseline periods.
  • Subjects have good daily habits and can maintain good communication with investigators and comply with various requirements of clinical trials.

Exclusion criteria

Exclusion Criteria:

  • Lactating women.
  • History of fainting with blood and needles.
  • Known or suspected allergy to study related products; or drug/food allergy history; or allergy-related diseases history.
  • Subjects who have participated in other clinical trials and given drugs or medical device interventions within 90 days before screening.
  • History of drug abuse within 1 year before screening, or positive results in drug abuse screening (urine).
  • Smokers who smoke ≥ 5 cigarettes per day within the previous 3 months before screening or cannot refrain from smoking throughout the trial period.
  • Any vaccine has been used within 28 days before administration, as well as any vaccine that may be used throughout the trial period.
  • Other scenarios judged by the investigator to render the subjects unsuitable for participating in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    GZR18

    Drug: GZR18

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugGZR18

    5 mg-maximum tolerated dose (MTD), single dose

  • OtherPlacebo

    administered the same volume as GZR18

07

What researchers measure

Primary outcomes

  1. TEAE

    Incidence of Treatment Emergent Adverse Event(s)

    Time frame: 50 days

  2. Anti-Drug Antibody (ADA) and Neutralizing Antibody (Nab)

    Time frame: 50 days

Secondary outcomes

  1. Cmax

    Maximum plasma drug concentration

    Time frame: 50 days

  2. AUClast

    area under the curve from 0 through the time of the last accurately measurable concentration

    Time frame: 50 days

  3. AUC0-inf

    area under the curve extrapolated to infinity

    Time frame: 50 days

  4. Tmax

    time to maximum plasma drug concentration

    Time frame: 50 days

  5. λz

    elimination rate constant

    Time frame: 50 days

  6. t1/2

    half-life

    Time frame: 50 days

  7. tlag

    lag time

    Time frame: 50 days

  8. CL/F

    apparent clearance

    Time frame: 50 days

  9. Vz/F

    volume of distribution/F

    Time frame: 50 days

  10. AUC%extra

    percent of AUC0-inf extrapolated

    Time frame: 50 days

  11. MRT

    mean residence time

    Time frame: 50 days

  12. Weight

    Time frame: 50 days

  13. Body Mass Index (BMI)

    Time frame: 50 days

08

Study locations

1 site
  • Gan & Lee Pharmaceuticals Co., Ltd
    Beijing, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Aug 2023, 3 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
Apr 25, 2023
Primary completionActual
Aug 14, 2023
CompletionActual
Aug 14, 2023
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06548945
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Apr 25, 2023
Primary completion
Aug 14, 2023
Completion
Aug 14, 2023
Last update
Aug 14, 2024

Study contacts

Liyuan Zhao, Ph.D
study director · Gan & Lee Pharmaceuticals.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion